Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells

SIMPLE SUMMARY: Cancer therapy by specifically redirected T cells has revolutionized the field of oncology. However, the repertoire of targetable antigens is small. Here, we use the FDA-approved drug decitabine to upregulate the surface antigen CSPG4 on CSPG4-negative ovarian carcinoma cells. By opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrer, Dennis Christoph, Schenkel, Charlotte, Berking, Carola, Herr, Wolfgang, Abken, Hinrich, Dörrie, Jan, Schaft, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599610/
https://www.ncbi.nlm.nih.gov/pubmed/36291817
http://dx.doi.org/10.3390/cancers14205033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599610/
https://www.ncbi.nlm.nih.gov/pubmed/36291817
http://dx.doi.org/10.3390/cancers14205033

Ejemplares similares